Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Amgen, Inc.
Medical Crossfire®: Leveraging T-Cell Engaging Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy, and the American Cancer Society estimates 6150 new diagnoses and 1520 deaths will occur in 2020. Progress is being made in terms of increased understanding of disease pathophysiology as related to identification of new cytogenetic and molecular abnormalities, as well as development of novel targeted agents for the treatment of ALL. The addition of tyrosine kinase inhibitors (TKIs), monoclonal antibodies, novel immune therapies, and chimeric antigen receptor (CAR) T cells to the treatment landscape has resulted in improved clinical outcomes. These new developments have shifted clinical management from a “one-size-fits-all” approach to a more individualized treatment approach based on immunophenotypic, cytogenetic, and molecular features.
This Medical Crossfire® will provide an ideal format for the ALL care team, inclusive of hematology-oncologists, to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing in-depth review of patient scenarios integrated with relevant evidence into real-world practice. Expert faculty will discuss methods to best integrate the latest therapies into the ALL treatment paradigms, address barriers to optimized integration of these novel agents, and provide best practices for the management of adverse events.
Benefits of Attending
- Hear how the experts and your peers are treating their patients with ALL, using examples from challenging, real-world cases
- Determine optimal treatment algorithms for specific patient groups across ALL
- Improve your knowledge about how emerging and cutting-edge treatments may be incorporated into your clinical practice
- Fine-tune your clinical skills for preventing and/or minimizing treatment-related adverse events for your patients with ALL
This educational activity is directed toward hematologists, medical oncologists, and other health care professionals interested in the latest advances in the treatment of patients with ALL.
Learning ObjectivesUpon completion of this activity, participants will be able to:
- Describe the biology of ALL in terms of biomarkers, testing strategies, and methods to stratify risk for patients with this hematologic malignancy
- Outline the role of T-cell–engaging immunotherapy in measurable residual disease status in treatment decisions for patients with ALL
- Incorporate key findings from recent clinical trials concerning the use of T-cell–engaging immunotherapy treatment strategies for patients with ALL in the frontline and relapsed/refractory settings into practice
Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Amgen, Inc.
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Registration2 Ways to Register
- Online: click here.
- Phone: Please call (888) 949-0045 or (609) 378-3701.
2 Clarke Drive
Cranbury, NJ 08512
Registration Fee - Free
For registration assistance, please email email@example.com, or call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.
Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.
By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.
Meeting information is accurate at the time of posting.
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
You must be logged in to PER to register for this meeting
Or Register for PER now